+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Leflunomide"

Rheumatoid Arthritis Drugs Market Report 2025 - Product Thumbnail Image

Rheumatoid Arthritis Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Prescription Orthopedic Drugs Global Market Report 2025 - Product Thumbnail Image

Prescription Orthopedic Drugs Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
Psoriatic Arthritis - Pipeline Insight, 2025 - Product Thumbnail Image

Psoriatic Arthritis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Rheumatoid Arthritis - Pipeline Insight, 2025 - Product Thumbnail Image

Rheumatoid Arthritis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
From
From
From
From
Africa Anti-Rheumatic Drugs Market - Forecasts from 2023 to 2028 - Product Thumbnail Image

Africa Anti-Rheumatic Drugs Market - Forecasts from 2023 to 2028

  • Report
  • February 2023
  • 135 Pages
  • Africa
From
  • 14 Results (Page 1 of 1)
Loading Indicator

Leflunomide is a drug used to treat immune disorders, such as rheumatoid arthritis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis. It works by blocking the production of certain proteins that cause inflammation and joint damage. It is usually taken in pill form, but can also be administered as an injection. Leflunomide is a relatively new drug, having been approved by the US Food and Drug Administration in 1998. It is generally well-tolerated, with few side effects. Common side effects include nausea, diarrhea, and headache. The leflunomide market is growing, as more people are being diagnosed with immune disorders. It is a competitive market, with several companies offering their own versions of the drug. Companies in the leflunomide market include Sanofi, Pfizer, Merck, and AbbVie. Show Less Read more